Chemical
Browse
Active Pharmaceutical Ingredients
Bioactive chemicals
Agrochemicals
Search
Chemical Structure
Explore
Chemical Similarity
Transformation
Browse
Prodrugs
Drug Metabolites
Metabolite Datasets
Cytochrome P450
Homo sapiens »
CYP1
CYP2
CYP3
CYP4
CYP5
CYP7
CYP8
CYP11
CYP17
CYP19
CYP20
CYP21
CYP24
CYP26
CYP27
CYP39
CYP46
CYP51
Mus musculus
Danio rerio
Oncorhynchus mykiss
Comparison of CYPs
Biochemical Action
Browse
Target Level (ChEMBL)
Level 1
Level 2
Level 3
Level 4
Level 5
Level 6
Mechanism of action
Search
Mechanism of action
BLAST against human drug target
BLAST against selected species (UniProt)
Exposure
Browse
Monitoring data
Downloads
Web services
Bulk downloads
About
About EcoDrug+
Citing
Data Sources
FAQ
Contact Us
Versions
Display Options:
Molecule Type
Mechanism of Action
Route of Adminstration
Status
Therapeutic Indication
Number of compounds:
7959
PRETOMANID
(2019)
Small molecule
Unknown
ORAL
Approved
Tuberculosis; Tuberculosis, Pulmonary
PRETOMANID
×
Maximum Phase:
4
First Approval:
2019
UNII:
2XOI31YC4N
Molecule Type:
Small molecule
Molecular Formula:
C14H12F3N3O5
Molecular Weight:
359.26
AlogP:
2.67
PSA:
88.65
HBD:
0.0
HBA:
#RotB:
5.0
Source:
ALPELISIB
(2019)
Small molecule
PI3-kinase p110-alpha subunit inhibitor
ORAL
Approved
Breast Neoplasms; Neoplasms
ALPELISIB
×
Maximum Phase:
4
First Approval:
2019
UNII:
08W5N2C97Q
Molecule Type:
Small molecule
Molecular Formula:
C19H22F3N5O2S
Molecular Weight:
441.48
AlogP:
3.84
PSA:
101.21
HBD:
2.0
HBA:
#RotB:
4.0
Source:
TRIFAROTENE
(2019)
Small molecule
Retinoic acid receptor gamma agonist
TOPICAL
Approved
Acne Vulgaris
TRIFAROTENE
×
Maximum Phase:
4
First Approval:
2019
UNII:
0J8RN2W0HK
Molecule Type:
Small molecule
Molecular Formula:
C29H33NO4
Molecular Weight:
459.59
AlogP:
5.99
PSA:
70.0
HBD:
2.0
HBA:
#RotB:
7.0
Source:
ERDAFITINIB
(2019)
Small molecule
Fibroblast growth factor receptor inhibitor
ORAL
Approved
Carcinoma, Transitional Cell; Neoplasms; Urinary Bladder Neoplasms
ERDAFITINIB
×
Maximum Phase:
4
First Approval:
2019
UNII:
890E37NHMV
Molecule Type:
Small molecule
Molecular Formula:
C25H30N6O2
Molecular Weight:
446.56
AlogP:
4.18
PSA:
77.33
HBD:
1.0
HBA:
#RotB:
9.0
Source:
ELEXACAFTOR
(2019)
Small molecule
Cystic fibrosis transmembrane conductance regulator positive modulator
Unknown
Approved
Unknown
ELEXACAFTOR
×
Maximum Phase:
4
First Approval:
2019
UNII:
RRN67GMB0V
Molecule Type:
Small molecule
Molecular Formula:
C26H34F3N7O4S
Molecular Weight:
597.66
AlogP:
4.02
PSA:
124.24
HBD:
1.0
HBA:
#RotB:
8.0
Source:
TRICLABENDAZOLE
(2019)
Small molecule
Unknown
ORAL
Approved
Fascioliasis; Helminthiasis
TRICLABENDAZOLE
×
Maximum Phase:
4
First Approval:
2019
UNII:
4784C8E03O
Molecule Type:
Small molecule
Molecular Formula:
C14H9Cl3N2OS
Molecular Weight:
359.67
AlogP:
6.04
PSA:
37.91
HBD:
1.0
HBA:
#RotB:
3.0
Source:
ENTRECTINIB
(2019)
Small molecule
ALK tyrosine kinase receptor inhibitor
ORAL
Approved
Carcinoma, Non-Small-Cell Lung; Neoplasms
ENTRECTINIB
×
Maximum Phase:
4
First Approval:
2019
UNII:
L5ORF0AN1I
Molecule Type:
Small molecule
Molecular Formula:
C31H34F2N6O2
Molecular Weight:
560.65
AlogP:
5.03
PSA:
85.52
HBD:
3.0
HBA:
#RotB:
7.0
Source:
UPADACITINIB
(2019)
Small molecule
Janus Kinase (JAK) inhibitor
ORAL
Approved
Arthritis, Rheumatoid; Immune System Diseases
UPADACITINIB
×
Maximum Phase:
4
First Approval:
2019
UNII:
4RA0KN46E0
Molecule Type:
Small molecule
Molecular Formula:
C17H19F3N6O
Molecular Weight:
380.37
AlogP:
2.91
PSA:
78.32
HBD:
2.0
HBA:
#RotB:
3.0
Source:
RELEBACTAM
(2019)
Small molecule
Bacterial beta-lactamase TEM inhibitor
Unknown
Approved
Intraabdominal Infections; Pyelonephritis; Urinary Tract Infections
RELEBACTAM
×
Maximum Phase:
4
First Approval:
2019
UNII:
Y1MYA2UHFL
Molecule Type:
Small molecule
Molecular Formula:
C12H20N4O6S
Molecular Weight:
348.38
AlogP:
-1.14
PSA:
128.28
HBD:
3.0
HBA:
#RotB:
4.0
Source:
DAROLUTAMIDE
(2019)
Small molecule
Androgen Receptor antagonist
ORAL
Approved
Neoplasms; Prostatic Neoplasms
DAROLUTAMIDE
×
Maximum Phase:
4
First Approval:
2019
UNII:
X05U0N2RCO
Molecule Type:
Small molecule
Molecular Formula:
C19H19ClN6O2
Molecular Weight:
398.85
AlogP:
2.67
PSA:
119.62
HBD:
3.0
HBA:
#RotB:
6.0
Source:
LUMATEPERONE
(2019)
Small molecule
Dopamine D2 receptor antagonist
Unknown
Approved
Psychotic Disorders
LUMATEPERONE
×
Maximum Phase:
4
First Approval:
2019
UNII:
70BSQ12069
Molecule Type:
Small molecule
Molecular Formula:
C24H28FN3O
Molecular Weight:
393.51
AlogP:
3.92
PSA:
26.79
HBD:
0.0
HBA:
#RotB:
5.0
Source:
LUMATEPERONE TOSYLATE
(2019)
Small molecule
Unknown
Unknown
Approved
Schizophrenia
LUMATEPERONE TOSYLATE
×
Maximum Phase:
4
First Approval:
2019
UNII:
JIE88N006O
Molecule Type:
Small molecule
Molecular Formula:
C31H36FN3O4S
Molecular Weight:
565.71
AlogP:
3.92
PSA:
26.79
HBD:
0.0
HBA:
#RotB:
5.0
Source:
AMLODIPINE BENZOATE
(2019)
Small molecule
Voltage-gated L-type calcium channel blocker
ORAL
Approved
Coronary Artery Disease; Diabetes Mellitus; Heart Failure; Hypertension; Myocardial Infarction; Stroke
AMLODIPINE BENZOATE
×
Maximum Phase:
4
First Approval:
2019
UNII:
XD75TQ8A2P
Molecule Type:
Small molecule
Molecular Formula:
C27H31ClN2O7
Molecular Weight:
531.01
AlogP:
2.27
PSA:
99.88
HBD:
2.0
HBA:
#RotB:
8.0
Source:
PEXIDARTINIB HYDROCHLORIDE
(2019)
Small molecule
Macrophage colony stimulating factor receptor inhibitor
ORAL
Approved
Giant Cell Tumor of Tendon Sheath
PEXIDARTINIB HYDROCHLORIDE
×
Maximum Phase:
4
First Approval:
2019
UNII:
YS6WAI3XN7
Molecule Type:
Small molecule
Molecular Formula:
C20H16Cl2F3N5
Molecular Weight:
454.28
AlogP:
5.23
PSA:
66.49
HBD:
2.0
HBA:
#RotB:
5.0
Source:
SOLRIAMFETOL
(2019)
Small molecule
Unknown
ORAL
Approved
Attention Deficit Disorder with Hyperactivity
SOLRIAMFETOL
×
Maximum Phase:
4
First Approval:
2019
UNII:
939U7C91AI
Molecule Type:
Small molecule
Molecular Formula:
C10H14N2O2
Molecular Weight:
194.23
AlogP:
0.65
PSA:
78.34
HBD:
2.0
HBA:
#RotB:
4.0
Source:
FLUORODOPA
(2019)
Small molecule
Unknown
Unknown
Approved
Unknown
FLUORODOPA
×
Maximum Phase:
4
First Approval:
2019
UNII:
6WIZ27OUZ9
Molecule Type:
Small molecule
Molecular Formula:
C9H10FNO4
Molecular Weight:
215.18
AlogP:
0.19
PSA:
103.78
HBD:
4.0
HBA:
#RotB:
3.0
Source:
FEDRATINIB HYDROCHLORIDE
(2019)
Small molecule
Tyrosine-protein kinase JAK2 inhibitor
ORAL
Approved
Primary Myelofibrosis
FEDRATINIB HYDROCHLORIDE
×
Maximum Phase:
4
First Approval:
2019
UNII:
UH9J2HBQWJ
Molecule Type:
Small molecule
Molecular Formula:
C27H40Cl2N6O4S
Molecular Weight:
615.63
AlogP:
4.82
PSA:
108.48
HBD:
3.0
HBA:
#RotB:
10.0
Source:
SELENIOUS ACID
(2019)
Small molecule
Supplement
INTRAVENOUS
Approved
Unknown
SELENIOUS ACID
×
Maximum Phase:
4
First Approval:
2019
UNII:
F6A27P4Q4R
Molecule Type:
Small molecule
Molecular Formula:
H2O3Se
Molecular Weight:
128.97
AlogP:
None
PSA:
None
HBD:
None
HBA:
#RotB:
None
Source:
LEFAMULIN
(2019)
Small molecule
Unknown
Unknown
Approved
Bacterial Infections
LEFAMULIN
×
Maximum Phase:
4
First Approval:
2019
UNII:
21904A5386
Molecule Type:
Small molecule
Molecular Formula:
C28H45NO5S
Molecular Weight:
507.74
AlogP:
3.87
PSA:
109.85
HBD:
3.0
HBA:
#RotB:
5.0
Source:
FEDRATINIB
(2019)
Small molecule
Tyrosine-protein kinase JAK2 inhibitor
Unknown
Approved
Neoplasms
FEDRATINIB
×
Maximum Phase:
4
First Approval:
2019
UNII:
6L1XP550I6
Molecule Type:
Small molecule
Molecular Formula:
C27H36N6O3S
Molecular Weight:
524.69
AlogP:
4.82
PSA:
108.48
HBD:
3.0
HBA:
#RotB:
10.0
Source:
TENAPANOR HYDROCHLORIDE
(2019)
Small molecule
Sodium/hydrogen exchanger 3 inhibitor
ORAL
Approved
Constipation; Irritable Bowel Syndrome
TENAPANOR HYDROCHLORIDE
×
Maximum Phase:
4
First Approval:
2019
UNII:
50605O2ZNS
Molecule Type:
Small molecule
Molecular Formula:
C50H68Cl6N8O10S2
Molecular Weight:
1217.99
AlogP:
None
PSA:
None
HBD:
None
HBA:
#RotB:
None
Source:
TENAPANOR
(2019)
Small molecule
Unknown
Unknown
Approved
Constipation
TENAPANOR
×
Maximum Phase:
4
First Approval:
2019
UNII:
WYD79216A6
Molecule Type:
Small molecule
Molecular Formula:
C50H66Cl4N8O10S2
Molecular Weight:
1145.07
AlogP:
None
PSA:
None
HBD:
None
HBA:
#RotB:
None
Source:
CEFIDEROCOL
(2019)
Small molecule
Bacterial penicillin-binding protein inhibitor
Unknown
Approved
Bacterial Infections
CEFIDEROCOL
×
Maximum Phase:
4
First Approval:
2019
UNII:
SZ34OMG6E8
Molecule Type:
Small molecule
Molecular Formula:
C30H34ClN7O10S2
Molecular Weight:
752.23
AlogP:
-0.18
PSA:
256.9
HBD:
6.0
HBA:
#RotB:
13.0
Source:
BREXANOLONE
(2019)
Small molecule
GABA-A receptor; anion channel positive allosteric modulator
INTRAVENOUS
Approved
Depression, Postpartum
BREXANOLONE
×
Maximum Phase:
4
First Approval:
2019
UNII:
S39XZ5QV8Y
Molecule Type:
Small molecule
Molecular Formula:
C21H34O2
Molecular Weight:
318.5
AlogP:
4.6
PSA:
37.3
HBD:
1.0
HBA:
#RotB:
1.0
Source:
PSMA-HBED-CC
(2020)
Small molecule
Unknown
Unknown
Investigational
Unknown
PSMA-HBED-CC
×
Maximum Phase:
4
First Approval:
2020
UNII:
9AG41L3AOQ
Molecule Type:
Small molecule
Molecular Formula:
C44H59GaN6O17
Molecular Weight:
1013.7
AlogP:
None
PSA:
None
HBD:
None
HBA:
#RotB:
None
Source:
OSILODROSTAT PHOSPHATE
(2020)
Small molecule
Cytochrome P450 11B1 inhibitor
Unknown
Approved
Pituitary ACTH Hypersecretion
OSILODROSTAT PHOSPHATE
×
Maximum Phase:
4
First Approval:
2020
UNII:
Y6581YAW9V
Molecule Type:
Small molecule
Molecular Formula:
C13H13FN3O4P
Molecular Weight:
325.24
AlogP:
2.43
PSA:
41.61
HBD:
0.0
HBA:
#RotB:
1.0
Source:
SELUMETINIB SULFATE
(2020)
Small molecule
Dual specificity mitogen-activated protein kinase kinase; MEK1/2 inhibitor
Unknown
Approved
Neurofibromatoses; Neurofibromatosis 1
SELUMETINIB SULFATE
×
Maximum Phase:
4
First Approval:
2020
UNII:
807ME4B7IJ
Molecule Type:
Small molecule
Molecular Formula:
C17H17BrClFN4O7S
Molecular Weight:
555.77
AlogP:
3.53
PSA:
88.41
HBD:
3.0
HBA:
#RotB:
6.0
Source:
MAGNESIUM OXYBATE
(2020)
Small molecule
GABA-B receptor agonist
Unknown
Approved
Unknown
MAGNESIUM OXYBATE
×
Maximum Phase:
4
First Approval:
2020
UNII:
G983HLV265
Molecule Type:
Small molecule
Molecular Formula:
C8H14MgO6
Molecular Weight:
230.5
AlogP:
-0.16
PSA:
57.53
HBD:
2.0
HBA:
#RotB:
3.0
Source:
LASMIDITAN
(2020)
Small molecule
Serotonin 1f (5-HT1f) receptor agonist
ORAL
Approved
Migraine Disorders
LASMIDITAN
×
Maximum Phase:
4
First Approval:
2020
UNII:
760I9WM792
Molecule Type:
Small molecule
Molecular Formula:
C19H18F3N3O2
Molecular Weight:
377.37
AlogP:
3.28
PSA:
62.3
HBD:
1.0
HBA:
#RotB:
4.0
Source:
CALCIUM OXYBATE
(2020)
Small molecule
GABA-B receptor agonist
Unknown
Approved
Unknown
CALCIUM OXYBATE
×
Maximum Phase:
4
First Approval:
2020
UNII:
8W24SYD6ZI
Molecule Type:
Small molecule
Molecular Formula:
C8H14CaO6
Molecular Weight:
246.27
AlogP:
-0.16
PSA:
57.53
HBD:
2.0
HBA:
#RotB:
3.0
Source:
SELPERCATINIB
(2020)
Small molecule
Coiled-coil domain-containing protein 6/Tyrosine-protein kinase receptor RET inhibitor
Unknown
Approved
Carcinoma, Medullary; Carcinoma, Non-Small-Cell Lung; Neoplasms; Thyroid Neoplasms
SELPERCATINIB
×
Maximum Phase:
4
First Approval:
2020
UNII:
CEGM9YBNGD
Molecule Type:
Small molecule
Molecular Formula:
C29H31N7O3
Molecular Weight:
525.61
AlogP:
3.28
PSA:
112.04
HBD:
1.0
HBA:
#RotB:
8.0
Source:
OSILODROSTAT
(2020)
Small molecule
Unknown
Unknown
Approved
Adrenal Gland Diseases
OSILODROSTAT
×
Maximum Phase:
4
First Approval:
2020
UNII:
5YL4IQ1078
Molecule Type:
Small molecule
Molecular Formula:
C13H10FN3
Molecular Weight:
227.24
AlogP:
2.43
PSA:
41.61
HBD:
0.0
HBA:
#RotB:
1.0
Source:
REMIMAZOLAM
(2020)
Small molecule
Unknown
Unknown
Approved
Unknown
REMIMAZOLAM
×
Maximum Phase:
4
First Approval:
2020
UNII:
7V4A8U16MB
Molecule Type:
Small molecule
Molecular Formula:
C21H19BrN4O2
Molecular Weight:
439.31
AlogP:
4.18
PSA:
69.37
HBD:
0.0
HBA:
#RotB:
4.0
Source:
NIFURTIMOX
(2020)
Small molecule
DNA inhibitor
Unknown
Approved
Chagas Disease; Leishmaniasis; Trypanosomiasis
NIFURTIMOX
×
Maximum Phase:
4
First Approval:
2020
UNII:
M84I3K7C2O
Molecule Type:
Small molecule
Molecular Formula:
C10H13N3O5S
Molecular Weight:
287.3
AlogP:
0.64
PSA:
106.02
HBD:
0.0
HBA:
#RotB:
3.0
Source:
RISDIPLAM
(2020)
Small molecule
SMN2 pre-mRNA positive modulator
Unknown
Approved
Atrophy; Muscular Atrophy, Spinal
RISDIPLAM
×
Maximum Phase:
4
First Approval:
2020
UNII:
76RS4S2ET1
Molecule Type:
Small molecule
Molecular Formula:
C22H23N7O
Molecular Weight:
401.47
AlogP:
1.96
PSA:
79.83
HBD:
1.0
HBA:
#RotB:
2.0
Source:
PRALSETINIB
(2020)
Small molecule
Coiled-coil domain-containing protein 6/Tyrosine-protein kinase receptor RET inhibitor
Unknown
Approved
Carcinoma, Medullary; Carcinoma, Non-Small-Cell Lung; Neoplasms
PRALSETINIB
×
Maximum Phase:
4
First Approval:
2020
UNII:
1WPE73O1WV
Molecule Type:
Small molecule
Molecular Formula:
C27H32FN9O2
Molecular Weight:
533.61
AlogP:
4.2
PSA:
135.53
HBD:
3.0
HBA:
#RotB:
8.0
Source:
1
2
…
70
71
72
73
74
75
76
…
221
222
Next »
Download Option
Header
Compound Name
Maximum Phase
Compound Structure
Smile
Inchi
InchiKey
Compound Properties
Molecular Formula
Molecular Weight
ALogP
PSA